title: Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.
abstract: A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
authors.affiliation: The Beatson, West of Scotland Cancer Centre, Glasgow, UK. bcsh@b-s-h.org.uk
authors.forename: Anne
authors.initials: A
authors.lastname: Parker
authors.forename: Kristin
authors.initials: K
authors.lastname: Bowles
authors.forename: J Andrew
authors.initials: JA
authors.lastname: Bradley
authors.forename: Vincent
authors.initials: V
authors.lastname: Emery
authors.forename: Carrie
authors.initials: C
authors.lastname: Featherstone
authors.forename: Girish
authors.initials: G
authors.lastname: Gupte
authors.forename: Robert
authors.initials: R
authors.lastname: Marcus
authors.forename: Jayan
authors.initials: J
authors.lastname: Parameshwar
authors.forename: Alan
authors.initials: A
authors.lastname: Ramsay
authors.forename: Charles
authors.initials: C
authors.lastname: Newstead
mesh_terms: D000328:Adult; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016219:Immunotherapy, Adoptive / Q000379:methods; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy*; D016377:Organ Transplantation / Q000009:adverse effects*; D011379:Prognosis; D012086:Reoperation; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab